ES2672526T3 - Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas - Google Patents

Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas Download PDF

Info

Publication number
ES2672526T3
ES2672526T3 ES09771199.8T ES09771199T ES2672526T3 ES 2672526 T3 ES2672526 T3 ES 2672526T3 ES 09771199 T ES09771199 T ES 09771199T ES 2672526 T3 ES2672526 T3 ES 2672526T3
Authority
ES
Spain
Prior art keywords
optionally substituted
drug
compound
formula
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09771199.8T
Other languages
English (en)
Spanish (es)
Inventor
Daniel V. Santi
Gary Ashley
Brian Hearn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolynx LLC
Original Assignee
Prolynx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx LLC filed Critical Prolynx LLC
Application granted granted Critical
Publication of ES2672526T3 publication Critical patent/ES2672526T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33303—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group
    • C08G65/33317—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing amino group heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES09771199.8T 2008-06-26 2009-06-26 Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas Active ES2672526T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US133148P 1999-05-07
US13314808P 2008-06-26 2008-06-26
US19205008P 2008-09-15 2008-09-15
US192050P 2008-09-15
PCT/US2009/048943 WO2009158668A1 (en) 2008-06-26 2009-06-26 Prodrugs and drug-macromolecule conjugates having controlled drug release rates

Publications (1)

Publication Number Publication Date
ES2672526T3 true ES2672526T3 (es) 2018-06-14

Family

ID=41444985

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09771199.8T Active ES2672526T3 (es) 2008-06-26 2009-06-26 Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas

Country Status (7)

Country Link
US (2) US8680315B2 (https=)
EP (1) EP2306986B1 (https=)
JP (2) JP6084770B2 (https=)
CN (1) CN102076331B (https=)
DK (1) DK2306986T3 (https=)
ES (1) ES2672526T3 (https=)
WO (1) WO2009158668A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703907B2 (en) * 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
EP2566334B1 (en) * 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
EP2566335B1 (en) * 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
BR112013031556B1 (pt) 2011-06-06 2022-03-29 Starpharma Pty Ltd Macromoléculas, uso das mesmas para tratar ou suprimir o crescimento de um câncer e composições farmacêuticas
WO2013036857A1 (en) * 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
KR102109067B1 (ko) 2011-09-07 2020-05-13 프로린크스 엘엘시 생분해성 교차결합을 가지는 하이드로젤
US20140256626A1 (en) * 2011-10-18 2014-09-11 Prolynx Llc Peg conjugates of exenatide
CA2873112A1 (en) * 2012-05-11 2013-11-14 Alexander Krantz Site-specific labeling and targeted delivery of proteins for the treatment of cancer
SG10201803370XA (en) * 2013-10-22 2018-06-28 Prolynx Llc Conjugates of somatostatin and its analogs
JP6701077B2 (ja) 2013-12-19 2020-05-27 シアトル ジェネティックス， インコーポレイテッド 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom
US20180022780A1 (en) 2014-09-26 2018-01-25 Bayer Pharma Aktiengesellschaft Stabilization adrenomedullin derivatives and use thereof
GB201508024D0 (en) * 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions
EP3922269A1 (en) * 2016-03-16 2021-12-15 Prolynx LLC Extended release conjugates of exenatide analogs
CN106177977B (zh) * 2016-07-11 2020-09-04 天津科技大学 一种抗肿瘤药物三元偶联物及合成和应用
TWI773730B (zh) 2017-02-22 2022-08-11 瑞典商阿斯特捷利康公司 治療性樹枝狀聚合物
MX2020007306A (es) 2018-01-12 2020-09-25 Prolynx Llc Tratamiento sinergico de cancer.
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
BR112021000658A2 (pt) 2018-07-19 2021-04-13 Starpharma Pty Ltd Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero
JPWO2020050378A1 (ja) * 2018-09-06 2021-08-30 生化学工業株式会社 第３級アミン化合物又はイミン化合物を結合させた、ポリマーコンジュゲートとその製造方法
US20220040318A1 (en) * 2018-09-28 2022-02-10 Seikagaku Corporation Primary amine compound or secondary amine compound-acidic polysaccharide conjugate and production method therefor
WO2020206358A1 (en) * 2019-04-05 2020-10-08 Prolynx Llc Improved conjugation linkers
CA3143584A1 (en) 2019-06-18 2020-12-24 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
EP4010041A4 (en) 2019-08-07 2024-12-11 Prolynx LLC Steam sterilization of hydrogels crosslinked by beta-eliminative linkers
CN110423355B (zh) * 2019-08-29 2021-09-14 武汉轻工大学 羧甲基化莲藕多糖-曲古霉素a轭合物的制备方法
CA3153644A1 (en) 2019-09-30 2021-04-08 Beijing Xuanyi Pharmasciences Co., Ltd. Protein-macromolecule conjugates and methods of use thereof
AR121891A1 (es) 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
EP4319821A1 (en) * 2021-04-09 2024-02-14 Nanjing University Conjugate and the preparing method and use thereof
WO2024235071A1 (en) * 2023-05-16 2024-11-21 Nanjing University Conjugate and the preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0270595B1 (en) * 1986-05-16 1990-08-16 Eka Nobel Ab An optically active reagent and a method for the determination of enantiomeric amine compounds
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
CA2262502C (en) * 1996-07-31 2002-11-26 Nikken Chemicals Co., Ltd. 6-phenyltetrahydro-1,3-oxazin-2-one derivatives and pharmaceutical composition containing the same
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
JPH11130711A (ja) * 1997-10-24 1999-05-18 Teijin Ltd １α，２４，２５−トリヒドロキシビタミンＤ３類の合成中間体およびその製造法
AU1345600A (en) * 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6114566A (en) * 1999-05-24 2000-09-05 Board Of Trustees Operating Michigan State University 4-cyano-3-hydroxybutanoyl hydrazines, derivatives and process for the preparation thereof
EP1210093A4 (en) * 1999-09-03 2005-01-12 Polytherics Ltd DEGRADABLE POLYMERS
US6861162B2 (en) 2002-08-28 2005-03-01 Cityu Research Ltd. Organic electroluminescence devices using pyrazolo[3,4b]quinoxaline derivatives
CA2521784C (en) 2003-04-08 2012-03-27 Yeda Research And Development Co. Ltd. Reversible pegylated drugs
US20070027073A1 (en) 2003-04-08 2007-02-01 Menachem Rubinstein Long-acting derivatives of pyy agonists
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
GB0319759D0 (en) * 2003-08-22 2003-09-24 Astrazeneca Ab Chemical compounds
MXPA06010782A (es) 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
JP2006067889A (ja) 2004-09-01 2006-03-16 Japan Science & Technology Agency Ｐｅｏと二本鎖核酸のコンジュゲート
WO2006094269A2 (en) 2005-03-03 2006-09-08 Covx Technologies Ireland Limited Anti-angiogenic compounds
CA2619533C (en) 2005-08-17 2014-02-04 Bioneer Corporation Sirna-hydrophilic polymer conjugates for intracellular delivery of sirna and method thereof
JP5224016B2 (ja) * 2006-03-10 2013-07-03 晃二 有光 感活性エネルギー線塩基発生剤、感活性エネルギー線塩基発生剤組成物、塩基反応性組成物及びパターン形成方法
US20100168443A1 (en) 2006-11-02 2010-07-01 University Of Virginia Patent Foundation Ethoid-Containing Compounds, Methods for Preparing Ethoid-Containing Compounds, and Methods of Use
HRP20161040T1 (hr) * 2008-04-29 2016-12-16 Ascendis Pharma Growth Disorders Division A/S Pegilirani rekombinantni spojevi ljudskog hormona rasta

Also Published As

Publication number Publication date
US20110263502A1 (en) 2011-10-27
DK2306986T3 (en) 2018-06-18
US20140296476A1 (en) 2014-10-02
WO2009158668A1 (en) 2009-12-30
US8680315B2 (en) 2014-03-25
CN102076331B (zh) 2013-12-18
JP6084770B2 (ja) 2017-02-22
US9387254B2 (en) 2016-07-12
CN102076331A (zh) 2011-05-25
EP2306986A1 (en) 2011-04-13
EP2306986A4 (en) 2015-01-28
EP2306986B1 (en) 2018-03-21
JP2015172078A (ja) 2015-10-01
JP2011528654A (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
ES2672526T3 (es) Profármacos y conjugados de fármaco-macromolécula que presentan velocidades de liberación de fármaco controladas
Rahimizadeh et al. Albumin: an emerging opportunity in drug delivery
ES2390816T3 (es) N,N-bis-(2-hidroxietil) glicina amida como ligador en profármacos conjugados con polímeros
JP7512207B2 (ja) 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法
ES2741524T3 (es) Profármaco polimérico con un enlazador autoinmolador
ES2791683T3 (es) Sistemas a base de conjugados para la administración controlada de fármacos
AU2015267200B2 (en) Nanoparticle drug conjugates
US20110294189A1 (en) Biomolecule polymer conjugates and methods for making the same
WO2014081301A1 (en) Bio-orthogonal drug activation
Zhang et al. Sulfonium-driven neoantigen-released DNA nanodevice as a precise vaccine for tumor immunotherapy and prevention
JP2013541510A (ja) 新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
JP2010090387A (ja) チオエステル末端化水溶性ポリマーおよびそれを用いてポリペプチドのｎ末端を改変する方法
CA3041950C (en) DELIVERY SYSTEM DESIGNED FOR THE TARGET DELIVERY OF A THERAPEUTICALLOUS PAYLOAD
IL267806B2 (en) Multimeric oligonucleotides having decreased kidney clearance
JP6814824B2 (ja) アポトーシスを誘導するための組成物及び方法
KR101223484B1 (ko) 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체
CN114392358A (zh) 一种肿瘤靶向的核酸适体药物偶连物
Pasut et al. A new PEG− β-alanine active derivative for releasable protein conjugation
JP2023501020A (ja) 治療用分子の標的化送達
KR20130022671A (ko) 전립선암 특이적 ｓｉＲＮＡ 전달체
WO2010119158A1 (es) Ciclooligosacáridos anfifílicos policatiónicos y su uso como transportadores moleculares
Kwon et al. Site-Selective Anti-PD-L1 Antibody–MMAE Conjugate for Enhanced NSCLC Therapy
US20250049927A1 (en) Modified oligonucleotide-drug conjugate and use thereof
An et al. Bioreducible crosslinked cationic nanopolyplexes from clickable polyethylenimines enabling robust cancer gene therapy
JP2023546558A (ja) アミド結合を含むリンカー化合物